Latest Breaking News On - கதிர்வீச்சு மருந்து - Page 3 : comparemela.com
Published: May 05, 2021
NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) Anavex Life Sciences Corp. . (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Dr. Adebayo (Bayo) Laniyonu, as Senior Vice President for Nonclinical Development. Dr. Laniyonu has over 24 years’ experience with the US Food and Drug Administration (FDA).
“Dr. Laniyonu has an accomplished track record of working within the FDA,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “His depth of experience makes him an excellent choice to provide objective perspective and manage the continuous nonclinical projects at Anavex.”
CanadaUnited-kingdomCanadianChristopheru-misslingAdebayo-bayo-laniyonuAndrewj-barwickiLinkedinCompany-nasdaqTwitterAward-for-distinguished-serviceResearch-business-developmentAdvisory-committeeHorrifying injuries of Chernobyl â from severe mutations to body collapsing
Although just 50 deaths have been attributed to the Chernobyl disaster, thousands of survivors suffered life-changing effects. Studies are still being carried out into the radiation s long-term impact
07:35, 26 APR 2021
The video will auto-play soon8Cancel
Play now
The Daily Star s FREE newsletter is spectacular! Sign up today for the best stories straight to your inboxInvalid EmailSomething went wrong, please try again later.
Sign up today!
When you subscribe we will use the information you provide to send you these newsletters. Your information will be used in accordance with ourPrivacy Notice.
Thank you for subscribingWe have more newslettersShow meSee ourprivacy notice
RussiaMoscowMoskvaUkraineKyivKyyivMistoBelarusUkrainianSovietTimothy-mousseauOleksiy-breus